Welcome to CCST


CCST provides excellent world class research facilities and the expertise to perform early Phase I and II studies. Since the late 1990’s CCST has become a major provider of clinical trials to the pharmaceutical industry. Quality is an integral part of clinical trials.  CCST is routinely audited 3 to 4 times per year by Sponsors and was FDA inspected in May 2017.

For further information, please contact Jo Sanders our Operation Manager jo@ccst.co.nz


CCST undertakes medical research in many therapeutic areas .  We conduct clinical studies which involve healthy people as well as specific disease groups.  To take part in a clinical study at CCST you need to register. Register Here.


Christchurch doctors have, over many years, been involved in a wide range of clinical trials for the pharmaceutical industry. A need was identified for a well designed and dedicated facility to perform Phase I and II pharmacokinetic and pharmacodynamic studies in healthy volunteer and patient populations.

Current Studies


CCST study information is now emailed out via a email service. Please check your mailing promotions and spam folders for CCST study emails. To ensure you receive your emails from CCST: Add the CCST email address to your Google Contacts or Move your CCST emails to the Primary tab and Gmail will learn that you wish to receive emails from CCST.  Thanks for your help !

We have recently mailed out the SIMBA study information. We are expecting a big response so please note it may take us a week or so to get back to you. 


Investigating the safety and tolerability of inhaled GDL- 0214

Males and Females

Age: 18 to 65 years

No significant health issues (to be confirmed by the Study doctor) 

Investigational Study Drug

Requirements:  4 night in-house stay and 3 clinic visits.

 Read more …


Study to investigate the safety and tolerability of a single dose of the trial drug CMX 521

Age 18-60

Gender Males and Females – females need to be of non child bearing potential

Overall Status Recruiting

Study Type Safety and Tolerability of a new medication

Requirements  2 night in stay and 5 clinic visits

Read more …


Age 18 to 55 Years
Gender Males and Females

No significant health issues (to be confirmed by study doctor)

Study Type: Evaluating equivalence of MSB11456 (Tocilizumab proposed biosimilar) with the Tocilizumab that is approved in both the USA and the EU

Requirements: Single dose of the study drug , 3 night inpatient stay and 10 clinic visits

Please note for this study you need to weigh over 60kg and not be on any medications

Read more …

Contact Us

Do not hesitate to contact Us!


0800 TO CCST or +64 3 372 9477


+64 3 3729478



CCST needs people to participate in our clinical research

CCST provides world class research facilities and expertise